Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study-Reference-Cited by-同舟云学术

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study

Published:2020-03-22 Issue:5 Volume:40 Page:1042-1051
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Asselah Tarik¹²^ORCID,Pol Stanislas³^ORCID,Hezode Christophe⁴,Loustaud‐Ratti Veronique⁵,Leroy Vincent⁶,Ahmed Si Nafa Si⁷,Ozenne Violaine⁸,Bronowicki Jean‐Pierre⁹,Larrey Dominique¹⁰,Tran Albert¹¹¹²¹³,Alric Laurent¹⁴,Nguyen‐Khac Eric¹⁵^ORCID,Robertson Michael N.¹⁶,Hanna George J.¹⁶,Brown Deborah¹⁶,Asante‐Appiah Ernest¹⁶,Su Feng‐Hsiu¹⁶,Hwang Peggy¹⁶,Hall Jessie Durrand¹⁶,Guidoum Amir¹⁶,Hagen Karin¹⁶,Haber Barbara A.¹⁶,Talwani Rohit¹⁶,Serfaty Lawrence¹⁷

Affiliation:

1. Department of Hepatology and Gastroenterology University Paris Diderot, Sorbonne Paris Cité, CRI, UMR 1149 INSERM Paris France

2. Department of Hepatology AP‐HP Hôpital Beaujon Clichy France

3. Department of Hepatology APHP Hôpital Cochin/Université Paris Descartes/INSERM U1223Institut Pasteur Paris France

4. Department of Hepatology Henri Mondor Hospital APHP, University of Paris‐Est, INSERM U955 Créteil France

5. Department of Hepatology and Gastroenterology CHU de Limoges U850 INSERM Université Limoges Limoges France

6. CHU de Grenoble Alpes Grenoble France

7. Department of Hepatology and Gastroenterology Pȏle de Recherche Clinique Hôpital Saint Joseph Marseille France

8. Department of Hepatology and Gastroenterology Hôpital Saint Antoine Paris France

9. Department of Hepatology and Gastroenterology CHU de Nancy Nancy France

10. Department of Hepatology Hôpital Saint Eloi Ecole de Médecine de Montpellier Montpellier France

11. Department of Gastroenterology Université Côte d'Azur Nice France

12. Centre Digestif CHU de Nice Nice France

13. INSERM, U1065, C3M, Team 8 Nice France

14. Department of Internal Medicine/Gastroenterology CHU de Toulouse Toulouse France

15. Department of Hepatology and Gastroenterology CHU de Amiens Amiens France

16. Department of Infectious Diseases Merck & Co., Inc. Kenilworth NJ USA

17. Department of Hepatology Hôpital de Hautepierre Universitaires de Strasbourg Strasbourg France

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14313

Reference17 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus infection

2. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

3. Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6

4. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r

5. Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of chronic viral hepatitis c in perm Krai;Perm Medical Journal;2024-01-22

2. Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C;Russian Journal of Gastroenterology, Hepatology, Coloproctology;2023-06-04

3. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder;Drug and Alcohol Dependence;2022-05

4. The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial;Saudi Journal of Gastroenterology;2022

5. Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct‐acting antivirals;Hepatology Research;2021-05-26